Revive Therapeutics Update:
A report released by Morningstar.com projected a fair trading value of $0.49 a share, that’s an increase of 0.13 cents from Friday’s close at $0.36 a share. Revive Therapeutics is a undervalued player in the Canadian biotechnology sector and the broader healthcare sector. If Revive can keep a stable cash burn, make strides in their clinical trials, and keep R&D costs economical, then it has a real shot in being a large and profitable company.
The Morningstar report covers the quantitative scores like quantitative moat, quantitative uncertainty and financial health of the company. Morningstar also covered the valuation and profitability of Revive Therapeutics . To read more into Revive Therapeutics please refer to the links below.
WHAT IS FAIR VALUE?
In accounting and economics, fair value is a rational and unbiased estimate of the potential market price of a good, service, or asset. It takes into account such objective factors as:
- acquisition/production/distribution costs, replacement costs, or costs of close substitutes
- actual utility at a given level of development of social productive capability
- supply vs. demand
and subjective factors such as
- risk characteristics
- cost of and return on capital
- individually perceived utility
Read more at http://legaliq.com/Definition/Fair_Value#@1h-ji:r2